Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic.

Nixon S, Bezverbnaya K, Maganti M, Gullane P, Reedijk M, Kuruvilla J, Prica A, Kridel R, Kukreti V, Bennett S, Rogalla P, Delabie J, Pintilie M, Crump M.

J Oncol Pract. 2019 Oct 1:JOP1900202. doi: 10.1200/JOP.19.00202. [Epub ahead of print]

PMID:
31573831
2.

Pembrolizumab for the treatment of diffuse large B-cell lymphoma.

Sheikh S, Kuruvilla J.

Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28.

PMID:
31456438
3.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.

PMID:
31398081
4.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM; ZOE-HSCT Study Group Collaborators.

JAMA. 2019 Jul 9;322(2):123-133. doi: 10.1001/jama.2019.9053. Erratum in: JAMA. 2019 Aug 27;322(8):785.

PMID:
31287523
5.

Optimal management of mantle cell lymphoma in the primary setting.

Tang C, Kuruvilla J.

Expert Rev Hematol. 2019 Sep;12(9):715-721. doi: 10.1080/17474086.2019.1639501. Epub 2019 Jul 19.

PMID:
31268728
6.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.

Vijenthira A, Maganti M, Kukreti V, Kuruvilla J, Tiedemann R, Chen C, Crump M, Prica A.

Leuk Lymphoma. 2019 Oct;60(10):2576-2579. doi: 10.1080/10428194.2019.1585837. Epub 2019 Apr 18. No abstract available.

PMID:
30997853
7.

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1158-1163. doi: 10.1016/j.bbmt.2019.01.014. Epub 2019 Jan 14.

PMID:
30654137
8.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
9.

Spatial and temporal characteristics of ambient atmospheric hydrocarbons in an active shale gas region in North Texas.

Lim GQ, Matin M, John K.

Sci Total Environ. 2019 Mar 15;656:347-363. doi: 10.1016/j.scitotenv.2018.11.313. Epub 2018 Nov 23.

PMID:
30513426
10.

Optimal frontline management of mantle cell lymphoma: can we agree?

Tang C, Kuruvilla J.

Expert Rev Hematol. 2018 Dec;11(12):911-914. doi: 10.1080/17474086.2018.1537778. Epub 2018 Nov 5. No abstract available.

PMID:
30336708
11.

A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

Reiman T, Savage KJ, Crump M, Cheung MC, MacDonald D, Buckstein R, Couban S, Piliotis E, Imrie K, Spaner D, Shivakumar S, Kuruvilla J, Villa D, Shepherd LE, Skamene T, Winch C, Chen BE, Hay AE.

Leuk Lymphoma. 2019 Apr;60(4):912-919. doi: 10.1080/10428194.2018.1515937. Epub 2018 Oct 10.

PMID:
30301414
12.

Significance of treatment response when managing patients with primary central nervous system lymphoma.

Chan H, Moraes FY, Berlin A, Crump M, Mason W, Laperriere N, Kuruvilla J, Prica A.

Leuk Lymphoma. 2019 Feb;60(2):349-357. doi: 10.1080/10428194.2018.1474524. Epub 2018 Jul 3.

PMID:
29966463
13.

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.

Kuruvilla J, Tzeng CH, Cho SG, Kim SJ, Tang JL, Su Y, Wu J, Vargo R, Cheverton P.

Bone Marrow Transplant. 2019 Feb;54(2):258-264. doi: 10.1038/s41409-018-0253-y. Epub 2018 Jun 12.

14.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Sep 10;36(26):2748.

15.

Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia.

Xu J, Nault RJ, Maldonado-Naranjo A, Frizon LA, John K, Holman K, Nagel SJ.

J Clin Neurosci. 2018 Apr;50:127-128. doi: 10.1016/j.jocn.2018.01.057. Epub 2018 Feb 7.

PMID:
29428267
16.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

17.

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review.

Mayo SJ, Kuruvilla J, Laister RC, Ayala AP, Alm M, Byker W, Kelly DL, Saligan L.

BMJ Open. 2018 Jan 27;8(1):e017578. doi: 10.1136/bmjopen-2017-017578. Review.

18.

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J.

Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.

PMID:
29276022
19.

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.

Falcone U, Jiang H, Bashir S, Tsang R, Kukreti V, Keating A, Crump M, Kuruvilla J.

Bone Marrow Transplant. 2018 Mar;53(3):347-351. doi: 10.1038/s41409-017-0054-8. Epub 2017 Dec 21. No abstract available.

PMID:
29269808
20.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group.

N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: N Engl J Med. 2018 Mar 1;378(9):878.

Supplemental Content

Loading ...
Support Center